Abstract
An ABAB reversal design with matched placebo was employed to assess the acetylcholine precursor, deanol, in the treatment of tardive dyskinesia. Oral dyskinesia was monitored by electromyography in four patients with tardive dyskinesia. A battery of psychological rating scales was also utilized to determine effects of deanol on psychological functioning. Improvement ranged from 35 to 70% dyskinetic symptom reduction in three patients given deanol. The decrease in symptomatology, however, did not reach the level of oral EMG activity observed in a normal control subject. Psychological functioning was generally unaffected, but slight improvement was seen in two subjects.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
